Cited 12 times in
Clinical Efficacy of a 24-months Course of Lamivudine Therapy in Patients with HBeAg Negative Chronic Hepatitis B: A Long-term Prospective Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김도영 | - |
dc.contributor.author | 김자경 | - |
dc.contributor.author | 박준용 | - |
dc.contributor.author | 백용한 | - |
dc.contributor.author | 안상훈 | - |
dc.contributor.author | 이관식 | - |
dc.contributor.author | 전재윤 | - |
dc.contributor.author | 한광협 | - |
dc.date.accessioned | 2015-04-23T17:03:11Z | - |
dc.date.available | 2015-04-23T17:03:11Z | - |
dc.date.issued | 2010 | - |
dc.identifier.issn | 1011-8934 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/101733 | - |
dc.description.abstract | The optimal duration of oral nucleos(t)ide analogue therapy for HBeAg negative chronic hepatitis B (CHB) has not been defined. The aim of this study was to investigate the clinical efficacy of 24-months course of lamivudine therapy in patients with HBeAg negative CHB in Korea. A total of 50 Korean patients with HBeAg negative CHB were prospectively enrolled. The patients received 100 mg/day of lamivudine orally for 24 months. Patients who showed complete response at 24 months to lamivudine therapy stopped treatment, and regular follow-up was done thereafter. The mean follow-up duration after cessation of therapy was 40.8+/-22.7 (range 12-96) months. The complete response rate at months 12 and 24 were 86.0% (43/50) and 86.0% (43/50), respectively, and the clinical breakthrough at months 12 and 24 were 4.0% (2/50) and 14.0% (7/50), respectively. The expected durability of responses at months 12, 24, and 36 after cessation of lamivudine therapy in 43 complete responders was 79.1%, 64.0%, and 56.9%, respectively. In conclusion, a 24-months course of lamivudine therapy shows high end-treatment response rate and substantial durability of initial response after cessation of therapy in HBeAg negative CHB patients in Korea | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 882~887 | - |
dc.relation.isPartOf | JOURNAL OF KOREAN MEDICAL SCIENCE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antiviral Agents/therapeutic use* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Hepatitis B e Antigens/blood* | - |
dc.subject.MESH | Hepatitis B, Chronic/drug therapy* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lamivudine/therapeutic use* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Recurrence | - |
dc.subject.MESH | Time Factors | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Clinical Efficacy of a 24-months Course of Lamivudine Therapy in Patients with HBeAg Negative Chronic Hepatitis B: A Long-term Prospective Study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Yong Han Paik | - |
dc.contributor.googleauthor | Ja Kyung Kim | - |
dc.contributor.googleauthor | Do Young Kim | - |
dc.contributor.googleauthor | Jun Yong Park | - |
dc.contributor.googleauthor | Sang Hoon Ahn | - |
dc.contributor.googleauthor | Kwang-Hyub Han | - |
dc.contributor.googleauthor | Chae Yoon Chon | - |
dc.contributor.googleauthor | Kwan Sik Lee | - |
dc.identifier.doi | 10.3346/jkms.2010.25.6.882 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00852 | - |
dc.contributor.localId | A01675 | - |
dc.contributor.localId | A01829 | - |
dc.contributor.localId | A02226 | - |
dc.contributor.localId | A02666 | - |
dc.contributor.localId | A04268 | - |
dc.contributor.localId | A03544 | - |
dc.contributor.localId | A00385 | - |
dc.relation.journalcode | J01517 | - |
dc.identifier.eissn | 1598-6357 | - |
dc.identifier.pmid | 20514309 | - |
dc.subject.keyword | Antiviral Agents | - |
dc.subject.keyword | Hepatitis B e Antigens | - |
dc.subject.keyword | Hepatitis B, Chronic | - |
dc.subject.keyword | Lamivudine | - |
dc.subject.keyword | Treatment Outcome | - |
dc.contributor.alternativeName | Kim, Do Young | - |
dc.contributor.alternativeName | Kim, Ja Kyung | - |
dc.contributor.alternativeName | Park, Jun Yong | - |
dc.contributor.alternativeName | Paik, Yong Han | - |
dc.contributor.alternativeName | Ahn, Sang Hoon | - |
dc.contributor.alternativeName | Lee, Kwan Sik | - |
dc.contributor.alternativeName | Chon, Chae Yoon | - |
dc.contributor.alternativeName | Han, Kwang Hyup | - |
dc.contributor.affiliatedAuthor | Kim, Ja Kyung | - |
dc.contributor.affiliatedAuthor | Park, Jun Yong | - |
dc.contributor.affiliatedAuthor | Paik, Yong Han | - |
dc.contributor.affiliatedAuthor | Ahn, Sang Hoon | - |
dc.contributor.affiliatedAuthor | Lee, Kwan Sik | - |
dc.contributor.affiliatedAuthor | Han, Kwang Hyup | - |
dc.contributor.affiliatedAuthor | Chon, Chae Yoon | - |
dc.contributor.affiliatedAuthor | Kim, Do Young | - |
dc.citation.volume | 25 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 882 | - |
dc.citation.endPage | 887 | - |
dc.identifier.bibliographicCitation | JOURNAL OF KOREAN MEDICAL SCIENCE, Vol.25(6) : 882-887, 2010 | - |
dc.identifier.rimsid | 46695 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.